United Kingdom

Central nervous system (CNS)

We focus on delivering solutions to patients and healthcare professionals via medicines and services for central nervous system disorders with a strong emphasis on multiple sclerosis, and other neurodegenerative disorders.


We concentrate on supporting the NHS in managing long-term conditions like multiple sclerosis and Parkinson's disease. Our aim is to work in partnership to develop joined-up care through Joint Working projects, to improve patient outcomes and enhance patient experience, and also to offer value for money. That might be through medicines optimisation, quality improvement, pathway redesign or improvement, innovation or identifying cost efficiencies.

Within Teva’s CNS medicines we have Copaxone® (glatiramer acetate) injection for the treatment of relapsing forms of multiple sclerosis and is available as a 20mg daily injection or as a 40mg three times weekly injection, and Azilect® (rasagiline) tablets which is for the treatment of the symptoms of Parkinson’s disease. 

Multiple Sclerosis
__________________________________________________________________________________________________________________

Multiple sclerosis (MS) is the most common cause of neurological disability in young adults and affects more than 2.5 million people worldwide.1 MS affects around 100,000 people in the UK.2 In the majority of patients, the disease is of the relapsing-remitting form (RRMS),3 which is manifested by relapses and slow progression of the disease that can affect the functioning of multiple systems.

Copaxone® (glatiramer acetate) 20mg

Copaxone® 20mg is indicated for the treatment of relapsing forms of multiple sclerosis. Copaxone® 20mg is not indicated in primary or secondary progressive multiple sclerosis.4

Copaxone® 20mg is supported by a comprehensive patient support programme.

Copaxone® (glatiramer acetate) 40mg

Copaxone® 40mg three times weekly is indicated for the treatment of relapsing forms of multiple sclerosis. It is not indicated for primary or secondary progressive multiple sclerosis.5

Copaxone 40mg also has a comparable safety profile to Copaxone 20mg.6

Copaxone 40mg has a lower incidence of injection site reactions compared to Copaxone 20mg6

For prescribing information please click here

Copaxone® 40mg is supported by a comprehensive patient support programme.


Parkinson’s disease
__________________________________________________________________________________________________________________

An estimated 10 million people worldwide are living with Parkinson's disease.7 The number of people diagnosed with Parkinson's in the UK is about 145,000. That's around 1 adult in every 350.8 There's currently no cure, but medicines and treatments are available to manage many of the symptoms.

Azilect® (rasagiline)

Azilect® is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease as initial monotherapy and as adjunct therapy to levodopa. Azilect® is an irreversible monoamine oxidase type B (MAO-B) inhibitor.9 


Further support for healthcare professionals
__________________________________________________________________________________________________________________

  • For factual scientific-based information about Copaxone® or Azilect® you can contact our Medical Information Service via e-mail medinfo@tevauk.com or call 0207 540 7117
  • Further information, including Prescribing Information for Copaxone® or Azilect® is available from the Copaxone® or Azilect® pages
  • You can also request a visit from a Teva representative here

Joint Working
__________________________________________________________________________________________________________________

Our Joint Working projects help the NHS and healthcare professionals deliver improved patient outcomes. Our Joint Working projects are available on our Joint Working pages.

To discuss potential Joint Working opportunities with Teva within CNS you can contact us and a representative from Teva will be in touch.

___________________________________________________________________________________________________

References:

[1] https://www.mstrust.org.uk/a-z/prevalence-and-incidence-multiple-sclerosis [accessed 17.04.18]. 

[2] http://www.mssociety.org.uk/what-is-ms [accessed 17.04.18]. 

[3] https://www.nice.org.uk/guidance/cg186/chapter/introduction [accessed 17.04.18]. 

[4] Copaxone® (glatiramer acetate) 20mg Summary of Product Characteristics. 

[5] Copaxone® (glatiramer acetate) 40mg Summary of Product Characteristics. 

[6] Khan O et al. Ann Neurol 2013: 73; 705–713. 

[7] http://parkinson.org/Understanding-Parkinsons/Causes-and-Statistics [accessed 17.04.18]. 

[8] https://www.parkinsons.org.uk/information-and-support/what-parkinsons [accessed 17.04.18]. 

[9] Azilect® (rasagiline) Summary of Product Characteristics.

Teva Ref: HC607